TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06605742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultancy
Description: In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultancy
Description: In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
Study: NCT06585904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 dose of Beetroot juice intake
Description: The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
Study: NCT06601296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)
Study: NCT06605690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib and Letrozole Combined With Anlotinib
Description: Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
Study: NCT06661772

Intervention type: DIAGNOSTIC_TEST
Intervention: Vancomycin trough concentration method
Description: A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
Study: NCT06600763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm gel pad
Description: Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
Study: NCT06592495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 4
Description: DWJ1589 or DWC202315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 4
Description: DWJ1589 or DWC202315
Study: NCT06605872

Intervention type: DEVICE
Intervention: GlucoTab
Description: Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).

Intervention type: OTHER
Intervention: Diabetes Treatment
Description: Diabetes Standard Care
Study: NCT06606054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational and implementation Neurocardiology tool
Description: Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No educational or implementation tool will be provided
Description: Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
Study: NCT06605105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYB003
Description: CYB003 is a synthetic psilocybin analog
Study: NCT06607458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
Description: Trifluridine-tipiracil plus Bevacizumab Alone
Study: NCT04845386

Intervention type: DEVICE
Intervention: TOF Cuff on arm
Description: The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Cuff on arm
Description: The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Cuff on lower leg
Description: The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on toe
Description: The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on adductor pollicis
Description: The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on adductor pollicis
Description: The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on adductor pollicis
Description: The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on adductor pollicis
Description: The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on corrugator supercilii
Description: The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Intervention: TOF Scan on corrugator supercilii
Description: The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
Study: NCT05325541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Biofeedback Therapy
Description: Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Balance exercise
Description: Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
Study: NCT06607458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine-tipiracil plus Bevacizumab Alone
Description: Trifluridine-tipiracil plus Bevacizumab Alone
Study: NCT06606535

Intervention type: DIAGNOSTIC_TEST
Intervention: validated questionnaires
Description: Validated questionnaires for climacteric symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: validated questionnaires
Description: Validated questionnaires for climacteric symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherent Tomography Angiography
Description: OCT angiography, macular and peripapillary scans
Study: NCT06346886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! HTN app
Description: Participants will remain in the intervention for 11 weeks. The app-based intervention is a tailored program to promote HTN self-management and knowledge through an 11-module educational video series with a focus on HTN. Participants will also be provided with at home Blood Pressure (BP) monitoring system to allow for self-tracking of BP measurements(automatically synchronized with the app). The app will include pre-post module quizzes, a tracking component for participants to input self-monitored measures (medication adherence, diet, physical activity, etc.). The app sharing board will be a moderated discussion platform and feed for participant interaction by posting healthy lifestyle practices through text, photographs and video to foster discussion on HTN management barriers/facilitators. The project team will post weekly to the sharing board on HTN-related topics to generate discussion among patients.
Study: NCT03459729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antitumor B
Description: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
Study: NCT05712356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
Study: NCT06606535

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherent Tomography Angiography
Description: OCT angiography, macular and peripapillary scans
Study: NCT06608199

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal disease prevention
Description: 2P+1 programme of PCV13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal disease prevention
Description: 2P+1 programme of PCV13
Study: NCT06026371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT06605781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AR/VR technology-based training
Description: Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional vedio and discussion group
Description: Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
Study: NCT06605183

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community walking program using Nordic walking poles
Description: This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
Study: NCT06702241

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light
Description: The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light
Description: The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light
Description: The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light
Description: The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
Study: NCT06720545

Intervention type: DEVICE
Group type: OTHER
Intervention: No HGNS therapy (HGNS-off)
Description: Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
Study: NCT06734793

Intervention type: DEVICE
Intervention: Wearable stethoscope
Description: The device is a soft, wearable stethoscope designed for continuous, comfortable monitoring of patients for abnormal breath sounds, such as wheezing, which can indicate asthma exacerbations. It automatically detects and diagnoses abnormal breath frequencies, wirelessly transmitting data for analysis. Preliminary materials have shown biocompatibility, ensuring the device is safe for use in children. A key feature is its machine-learning algorithm, which can classify and differentiate normal from abnormal sounds with an expected accuracy above 80%. Initial in vivo tests will compare the device's findings to those of a commercial-grade stethoscope in healthy subjects and individuals with asthma. Breath sound data will be used to improve the detection of wheezing sounds from these continuous recordings based on frequency and amplitude analysis of the recordings.

Intervention type: OTHER
Intervention: Routine Clinical lung Auscultation
Description: The study PI will auscultate the participant's lungs at enrollment to ensure that wheezing is present before beginning the continuous recording of the participant's lung sounds. The PI will assess the participant's respiratory status daily at the start of each breath sound recording session.
Study: NCT06737536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0662-0419
Description: Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0662-0419
Description: Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0662-0419)
Description: Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0662-0419)
Description: Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
Study: NCT06747364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol (Ethanol)
Description: Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.
Study: NCT06742346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non Tailored Messages
Description: Generic messages promoting a plant-based diet were developed, with each message addressing one of the three most commonly mentioned motives for plant-based eating (Miki et al., 2019; Miki et al., 2020): health motives, environmental motives, and animal welfare motives. All messages were designed to be factual (including science-based statistics), concise (4-5 sentences), relevant to teens (e.g., addressing health concerns like acne), and autonomy-supportive (offering suggestions and tips rather than directives) (Hingle et al., 2013). The messages were intentionally crafted in a neutral linguistic style, avoiding highly emotive language, non-standard syntax, or emojis. These messages are delivered from Monday to Friday for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non Tailored Messages
Description: Generic messages promoting a plant-based diet were developed, with each message addressing one of the three most commonly mentioned motives for plant-based eating (Miki et al., 2019; Miki et al., 2020): health motives, environmental motives, and animal welfare motives. All messages were designed to be factual (including science-based statistics), concise (4-5 sentences), relevant to teens (e.g., addressing health concerns like acne), and autonomy-supportive (offering suggestions and tips rather than directives) (Hingle et al., 2013). The messages were intentionally crafted in a neutral linguistic style, avoiding highly emotive language, non-standard syntax, or emojis. These messages are delivered from Monday to Friday for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistically tailored health messages
Description: Linguistically tailored messages are generated using a Large Language Model. Generic messages promoting a plant-based diet were customized to align with participants' linguistic style, including their preferred choice of words, expressed valence, syntax, and emoji use. These messages are delivered from Monday to Friday for two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistically tailored health messages
Description: Linguistically tailored messages are generated using a Large Language Model. Generic messages promoting a plant-based diet were customized to align with participants' linguistic style, including their preferred choice of words, expressed valence, syntax, and emoji use. These messages are delivered from Monday to Friday for two weeks.
Study: NCT06758141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: 3D Printed Advanced Cardiac Model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slide-based presentation
Description: Slide-based presentation
Study: NCT06757764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100mg qd (21days)~* In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd (21days)~* In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg qd (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg qd (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)
Study: NCT05712356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Durvalumab
Description: 1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)
Study: NCT06757764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol SR 100mg x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)